The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Novo NordiskNVO undercut Eli LillyLLY and the Trump administration on Monday, slashing the cash price of its drugs Wegovy and Ozempic to just $349 a month. That compares with $499 a month, previously, ...
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...
Novo Nordisk President and CEO Mike Doustdar speaks during an event about drug prices with President Donald Trump, Thursday, Nov. 6, 2025, in the Oval Office of the White House in Washington. (AP ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback